Antitumor activity of Hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4969-4975

  Shusterman, Suzanne ^a   London, Wendy B ^a   Gillies, Stephen D ^a   Hank, Jacquelyn A ^a   Voss, Stephan D ^a   Seeger, Robert C ^a   Reynolds, C Patrick ^a   Kimball, Jennifer ^a   Albertini, Mark R ^a   Wagner, Barrett ^a   Gan, Jacek ^a   Eickhoff, Jens ^a   DeSantes, Kenneth B ^a   Cohn, Susan L ^a   Hecht, Toby ^a   Gadbaw, Brian ^a   Reisfeld, Ralph A ^a   Maris, John M ^a   Sondel, Paul M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOPAMINE; EMD 273063; HEMOGLOBIN; INDOMETACIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CAPILLARY LEAK SYNDROME; CHILD; CLINICAL ARTICLE; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INFANT; INFECTION; LEUKOCYTE; LYMPHOCYTE; NEUROBLASTOMA; NEUTROPHIL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; THROMBOCYTE; URTICARIA; VENTILATORY SUPPORT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFANT; INTERLEUKIN-2; LYMPHOCYTE COUNT; NEUROBLASTOMA; RECEPTORS, INTERLEUKIN-2;

EID: 79951886003     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.8861     Document Type: Article

References (44)

1. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007 (Pubitemid 46935947)
2. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173, 1999 (Pubitemid 29480654)
3. Matthay KK, Reynolds CP, Seeger RC, et al: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol 27:1007-1013, 2009
4. Mujoo K, Spiro RC, Reisfeld RA: Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells. J Biol Chem 261:10299-10305, 1986 (Pubitemid 17221967)
5. Cheung NK, Saarinen UM, Neely JE, et al: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649, 1985 (Pubitemid 15024436)
6. Chang HR, Cordon-Cardo C, Houghton AN, et al: Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 70:633-638, 1992
7. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al: Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16:2169-2180, 1998 (Pubitemid 28265055)
8. Cheung NK, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma [see comments]. J Clin Oncol 5:1430-1440, 1987 (Pubitemid 18049879)
9. Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193, 1994 (Pubitemid 24020639)
10. Saleh MN, Khazaeli MB, Wheeler RH, et al: Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3:19-24, 1992
11. Handgretinger R, Baader P, Dopfer R, et al: A phase I study of neuroblastoma with the antiganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199-204, 1992
12. Lode HN, Xiang R, Duncan SR, et al: Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with singlechain IL-12. Proc Natl Acad Sci U S A 96:8591-8596, 1999 (Pubitemid 29354836)
13. Lode HN, Xiang R, Varki NM, et al: Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89:1586-1594, 1997 (Pubitemid 27479718)
14. Neal ZC, Yang JC, Rakhmilevich AL, et al: Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10:4839-4847, 2004 (Pubitemid 38955538)
15. Imai M, Landen C, Ohta R, et al: Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 65:10562-10568, 2005 (Pubitemid 41743751)
16. Munn DH, Cheung NK: Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47:6600-6605, 1987 (Pubitemid 18019663)
17. Hank JA, Robinson RR, Surfus J, et al: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50:5234-5239, 1990 (Pubitemid 20302968)
18. Barker E, Reisfeld RA: A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res 53:362-367, 1993 (Pubitemid 23031850)
19. Frost JD, Hank JA, Reaman GH, et al: A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group. Cancer 80:317-333, 1997 (Pubitemid 27282327)
20. Albertini MR, Hank JA, Schiller JH, et al: Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 3:1277-1288, 1997 (Pubitemid 27362388)
21. Hank JA, Surfus J, Gan J, et al: Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol 15:29-37, 1994 (Pubitemid 24005091)
22. Kushner BH, Kramer K, Cheung NK: Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189-4194, 2001 (Pubitemid 33081635)
23. Cheung NK, Sowers R, Vickers AJ, et al: FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti- GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24:2885-2890, 2006 (Pubitemid 46630590)
24. Ozkaynak MF, Sondel PM, Krailo MD, et al: Phase I study of chimeric human/murine antiganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study. J Clin Oncol 18: 4077-4085, 2000 (Pubitemid 32038400)
25. Gilman AL, Ozkaynak MF, Matthay KK, et al: Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from the Children's Oncology Group. J Clin Oncol 27:85-91, 2009
26. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al: Phase I trial of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16:2169-2180, 1998 (Pubitemid 28265055)
27. Yu AL, Gilman AL, Ozkaynak MF, et al: Chimeric anti-GD2 antibody with GM-CSF, IL2 and 13-Cis retinoic acid for high-risk neuroblastoma: A Children's Oncology Group (COG) phase 3 study. N Engl J Med (in press)
28. Gillies SD, Reilly EB, Lo KM, et al: Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A 89:1428-1432, 1992
29. Hank JA, Surfus JE, Gan J, et al: Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res 2:1951-1959, 1996
30. Voss SD, Robb RJ, Weil-Hillman G, et al: Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: P70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med 172:1101-1114, 1990 (Pubitemid 20343210)
31. Neal ZC, Imboden M, Rakhmilevich AL, et al: NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother 53:41-52, 2004 (Pubitemid 38161180)
32. Lode HN, Xiang R, Dreier T, et al: Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706-1715, 1998 (Pubitemid 28110336)
33. King DM, Albertini MR, Schalch H, et al: Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22:4463-4473, 2004 (Pubitemid 41185112)
34. Osenga KL, Hank JA, Albertini MR, et al: A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group. Clin Cancer Res 12:1750-1759, 2006
35. Seeger RC, Reynolds CP, Gallego R, et al: Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 18:4067-4076, 2000 (Pubitemid 32038399)
36. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
37. Matthay KK, Edeline V, Lumbroso J, et al: Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486-2491, 2003 (Pubitemid 46606329)
38. Gan J, Kendra K, Ricci M, et al: Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins. Clin Diagn Lab Immunol 6:236-242, 1999 (Pubitemid 29124971)
39. Hank JA, Gan J, Ryu H, et al: Immunogenicity of the Hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res 15:5923-5930, 2009
40. Kaplan EL, Meier P: Nonparametric-estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
41. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
42. Voss SD, Hank JA, Nobis CA, et al: Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 29:261-269, 1989 (Pubitemid 19166458)
43. Cheung NK, Cheung IY, Canete A, et al: Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228-2233, 1994
44. Cheung NK, Guo HF, Heller G, et al: Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 6:2653-2660, 2000 (Pubitemid 30482100)